← Catalyst calendarAVIR biotech catalysts & pipeline
ATEA PHARMACEUTICALS INC · Data as of 2026-09-08
Upcoming catalysts
bemnifosbuvir + ruzasvir — Topline data
Q1 2027
Looking ahead, we remain focused on delivering topline results from our second Phase 3 trial, C-FORWARD, in early first quarter 2027 while continuing to advance AT-587 for the treatment of HEV, where a substantial commercial opportunity remains due to the lack of any approved therapies
Source filingbemnifosbuvir + ruzasvir — NDA/BLA submission
Q2 2027
Following the recent topline readout for C-BEYOND and pending results from C-FORWARD, Atea anticipates submitting a new drug application (NDA) to the US Food & Drug Administration (FDA) in the second quarter of 2027.
Source filingExplore the free biotech catalyst calendar